About: Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
Sector: Healthcare
Industry: Biotechnology
Latest price: $2.05 (-6.82%)
PALINASDAQPalisade Bio Inc
Palisade Bio Inc share price
PALI price activity
Last Price
$2.050
Change (24hr)
-0.15 USD (-6.82%)
Volume
2.77M
Volume (4w avg)
-
Open
$2.17
Day Range
$2.05 - $2.21
Previous Close
$2.20
Last Trade
09 Sep, 8:00 pm GMT+0
Delayed
09 Sep, 8:00 pm GMT+0
PALI price performance
Delayed
09 Sep, 8:00 pm GMT+0
PALI Market Signals